Hot topics in antibody-drug conjugate development

被引:0
|
作者
Thudium, Karen [1 ]
Bilic, Sanela [1 ]
机构
[1] Novartis Pharmaceut, Clin Pharmacol, Oncol Business Unit, E Hanover, NJ 07936 USA
关键词
BIOANALYTICAL METHOD VALIDATION; MACROMOLECULES;
D O I
10.4155/BIO.13.276
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
American Association of Pharmaceutical Scientists National Biotechnology Conference Sheraton San Diego Hotel and Marina, San Diego, CA, USA, 19-23 May 2013 The National Biotechnology Conference, is a premier meeting for biotechnology professionals covering a broad range of hot topics in the biotechnology industry. Attracting participants from academia, industry and regulatory, this meeting features sessions that aim to address emerging subjects of interest and allows for open exchange between scientists. The 2013 conference featured leading researchers in the fields of antibody-drug conjugates (ADCs) and immunogenicity. Herein, we present a summary of the ADC hot topics, including bioanalytical and PK considerations, quantitative evaluation of the impact of immunogenicity and ADME to understand ADC drug-drug interactions, and clinical considerations for ADC development. This article aims to summarize the recommendations that were made by the speakers during various sessions throughout the conference.
引用
收藏
页码:2989 / 2993
页数:5
相关论文
共 50 条
  • [21] Development of a facile antibody-drug conjugate platform for increased stability and homogeneity
    Gupta, Nimish
    Kancharla, Johny
    Kaushik, Shelly
    Ansari, Aasif
    Hossain, Samad
    Goyal, Ravinder
    Pandey, Manoj
    Sivaccumar, Jwala
    Hussain, Sazid
    Sarkar, Arindam
    Sengupta, Aniruddha
    Mandal, Swadhin K.
    Roy, Monideepa
    Sengupta, Shiladitya
    CHEMICAL SCIENCE, 2017, 8 (03) : 2387 - 2395
  • [22] Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer
    Park, Jong Chul
    Shin, Donghoon
    JCO PRECISION ONCOLOGY, 2024, 8
  • [23] Development of a nitroreductase-dependent theranostic payload for antibody-drug conjugate
    Su, Zheng
    Xie, Fei
    Xu, Xin
    Liu, Lianqi
    Xiao, Dian
    Zhou, Xinbo
    Li, Song
    BIOORGANIC CHEMISTRY, 2022, 129
  • [24] Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma
    Mehta, Amitkumar
    Forero-Torres, Andres
    CURRENT ONCOLOGY REPORTS, 2015, 17 (09)
  • [25] Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer
    Park, Jong Chul
    Shin, Donghoon
    JCO PRECISION ONCOLOGY, 2024, 8
  • [26] Development of an antibody-drug conjugate against tissue factor for cancer therapy
    Tsumura, Ryo
    Anzai, Takahiro
    Takashima, Hiroki
    Koga, Yoshikatsu
    Matsumura, Yasuhiro
    Yasunaga, Masahiro
    CANCER SCIENCE, 2024, 115 : 617 - 617
  • [27] Pharmacist Involvement in Antibody-Drug Conjugate Therapy
    Mishiyeva, Oksana
    Farina, Kyle A.
    Rattu, Mohammad A.
    US PHARMACIST, 2022, 47 (01) : 34 - 55
  • [28] Antibody-drug Conjugate Targets, Drugs, and Linkers
    Teicher, Beverly A.
    Morris, Joel
    CURRENT CANCER DRUG TARGETS, 2022, 22 (06) : 463 - 529
  • [29] Photoinduced Aggregation of a Model Antibody-Drug Conjugate
    Cockrell, Gregory M.
    Wolfe, Michael S.
    Wolfe, Janet L.
    Schoeneich, Christian
    MOLECULAR PHARMACEUTICS, 2015, 12 (06) : 1784 - 1797
  • [30] Novel targets for antibody-drug conjugate therapy
    Grandi, A. G.
    Campagnoli, S. C.
    Parri, M. P.
    De Camilli, E. D. C.
    Jin, B. J.
    Sarmientos, P. S.
    Grandi, G. G.
    Terracciano, L. T.
    Pileri, P. P.
    Viale, G. V.
    Grifantini, R.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 41 - 41